Author: Kevo Burroughs

Growth stock investor with over 10 years hobby experience trading the markets.
AYTU Bioscience – AYTU

AYTU Bioscience – AYTU

Thoughts on today’s market action… Be cautious of words that begin with ‘T’! Fortunately for long term share holders, this may bring quality buying opportunities for companies who continue to exhibit decent, upbeat fundamentals as these will be the companies that will benefit the most from price appreciation once a comfortable buying atmosphere returns. Turning…

Read More Read More

1st Quarter 2019 – Update

1st Quarter 2019 – Update

PRPO – Precipio, Inc. As expected, the reverse split has been completed. So, how far down will we decline? While the company press releases have been positive over the last few months, the underlying fundamentals and financial environment that led to the slow decline, I believe, remains in place. Anticipated in the upcoming few weeks,…

Read More Read More

It’s Inevitable

It’s Inevitable

It’s closing in on a year, March 25th to be exact, of Precipio’s stock price not meeting Nasdaq’s listing price requirement. And it’s now down to the wire for management to make good on their claim in avoiding a reverse split to remain listed on the exchange. So, what now? Apparently, the rumor is that…

Read More Read More

Energous Corporation – WATT

Energous Corporation – WATT

Welcome to 2019! As a reminder, I often like to research and select companies that are in the pre-production or pre-commercialization stages of a company cycle. Where obviously, if executed efficiently by management, can provide significant returns on investment for any portfolio. One such qualifier and first pick of this year is Energous Corporation. The…

Read More Read More

Precipio – Undervalued?

Precipio – Undervalued?

According to Merriam-Webster, the definition of undervalue is a verb meaning: to value, rate, or estimate below the real worth. So does this apply to Precipio? At this current point in November, I would say it does. Precipio, Inc. is a growing company in the burgeoning liquid biopsy space that is visibly executing a strategy…

Read More Read More

EyePoint Pharmaceuticals, Inc. – EYPT

EyePoint Pharmaceuticals, Inc. – EYPT

EyePoint Pharmaceuticals, Inc. is a small cap company that is in the business of developing eye products via a ‘long-term, sustained release delivery’ platform. Their current products that have been developed, tested, and are ready for the market is DEXYCU and YUTIQ. Although not yet approved by the FDA, Yutiq I suspect will get the green…

Read More Read More

3rd Quarter 2018 – Portfolio Update

3rd Quarter 2018 – Portfolio Update

The year has been pretty positive so far with the markets and economy showing impressive gains. Hope you as well are being rewarded with gains. Below are my updates on my picks for the third quarter.   TRXC – TransEnterix is still showing signs of decent growth. The new addition of a commercial officer should…

Read More Read More

SIFY – Closing Position

SIFY – Closing Position

After review of this telecom company, which has already exceeded my target of 100% share price growth, I’ve decided to go ahead and take profits. Hovering around the $2 mark is what I foresee happening in the share price for the next few months. Sify Technologies Inc. seems to be experiencing growth in its’ Indian…

Read More Read More

Portfolio Update – XXII and PRPO

Portfolio Update – XXII and PRPO

As is customary with any semi-active trader, periodic review of the companies in your portfolio is both critically and obviously important to maintain meaningful growth. In other words, I think of each portfolio dollar as an employee of my company. As manager, you want to move employees into areas where they each will continue to…

Read More Read More

Precipio, Inc. – PRPO

Precipio, Inc. – PRPO

I’ve been watching the ebb and flow of the market, keeping an eye out for potential accelerated growth candidates and have identified a possible gem. This pick is Precipio, Inc. (PRPO). This small cap company is in the business of providing cancer diagnostic products and services to the oncology market. Precipio is expanding the potential…

Read More Read More